Siemens Healthineers Lands Six FDA Nods for AI Imaging Line, Hires Danaher AI Chief as CTO, While China Drags Guidance Lower

Siemens Healthineers gains FDA clearance for six AI-powered imaging systems and hires ex-Google Brain researcher as CTO, but weak China demand and rising costs trim earnings guidance.

Siemens Healthineers is pushing aggressively into artificial intelligence-driven diagnostics, but the market remains focused on the headwinds that have slashed nearly a third off the stock’s value over the past twelve months. The German medtech group has just been granted US regulatory clearance for six new imaging systems and poached a former Google Brain researcher as its next chief technology officer, yet the shares continue to trade just above their 52-week low as weak demand in China and rising supply-chain costs weigh on earnings.

Martin Stumpe will become Chief Technology Officer on June 1, 2026, succeeding Peter Schardt, who is retiring after more than seven years in the role. Stumpe joins from Danaher, where he served as Chief Technology & AI Officer, and previously founded and led the pathology team at Google Brain. His appointment underscores the company’s ambition to embed artificial intelligence in medical imaging, particularly in the areas of patient twinning and precision therapy – digital patient models designed to sharpen diagnostic accuracy. At the DMEA trade fair in Berlin he publicly outlined the concept, though concrete products or launch dates were not disclosed.

The technology push comes at a time when the operating picture is starkly divided. Second-quarter revenue for fiscal 2026 reached €5.7 billion, with comparable growth of 3.1%. Adjusted earnings per share, however, slid 6% to €0.53. Imaging was the standout, posting 6.1% growth, while precision therapy advanced 4.7%. The diagnostics segment was the sore spot, contracting 6.5% as conditions in China deteriorated. Management responded by trimming full-year revenue growth guidance to between 4.5% and 5.0%, down from the prior 5% to 6% range, and narrowed adjusted EPS expectations to €2.20–€2.30.

The FDA has meanwhile cleared six new systems in the Artis portfolio – the family of interventional radiology platforms used in minimally invasive procedures. The approved configurations include floor-mounted, biplane and robotic versions of Artis Vision, alongside specific variants of Artis icono.explore and Artis genio. All are equipped with the Optiq AI imaging chain, which uses algorithms to analyse image data in real time, boosting precision while keeping radiation doses in check for both patients and staff. Imaging, the segment these systems belong to, delivered an adjusted operating margin of 22.4% in the quarter, underscoring its role as the group’s core profit engine.

The planned spin-off of Siemens Healthineers from parent Siemens AG is taking shape. Shareholder votes at both companies are scheduled for early 2027, and a banking consortium has been lined up to refinance debt. Net debt, including pensions, stood at €13.2 billion at the end of March, equivalent to 3.1 times EBITDA. Moody’s has kept its A3 rating with a stable outlook for now.

Additional cost pressures are complicating the turnaround. The secondary article notes that more expensive memory chips and rising logistics bills are squeezing expectations, while the structural reorganisation in China adds further uncertainty. On top of the corporate spin-off, a separate potential spin-off of the diagnostics segment remains on the table as a strategic scenario through 2027.

At €34.17, the stock is within a whisker of its 52-week trough of €33.50 and sits roughly 21% below its 200-day moving average. Despite the operational successes in imaging and the fresh AI firepower in the C-suite, the market is clearly waiting for China to stabilise and for the new Artis systems to translate regulatory approvals into commercial traction before reassessing the risk-reward balance.